CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-04 | Dandekar Atul CSBO | Option exercise | +5,985 | $10.42 | $62K | 24,808 |
| 2026-05-04 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) | −8,320 | 20,204 | ||
| 2026-05-04 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) | −5,985 | 27,725 | ||
| 2026-05-04 | HOMCY CHARLES J Director | Gift | −7,422 | 31,113 | ||
| 2026-04-29 | Dandekar Atul CSBO | Option exercise 10b5-1 | +7,500 | $10.42 | $78K | 18,003 |
| 2026-04-29 | Dandekar Atul CSBO | Sale 10b5-1 | −7,500 | $25.37 | $190K | 10,503 |
| 2026-04-29 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 44,143 | ||
| 2026-04-01 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +2,500 | $10.42 | $26K | 15,465 |
| 2026-04-01 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −2,200 | $29.32 | $65K | 13,265 |
| 2026-04-01 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −300 | $30.34 | $9K | 12,965 |
| 2026-04-01 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,500 | 33,833 | ||
| 2026-04-01 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +15,000 | $10.42 | $156K | 15,000 |
| 2026-04-01 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −11,352 | $29.24 | $332K | 3,648 |
| 2026-04-01 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −3,348 | $30.06 | $101K | 300 |
| 2026-04-01 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −300 | $31.07 | $9K | 0 |
| 2026-04-01 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 237,407 | ||
| 2026-03-30 | Dandekar Atul CSBO | Option exercise 10b5-1 | +7,500 | $10.42 | $78K | 18,003 |
| 2026-03-30 | Dandekar Atul CSBO | Sale 10b5-1 | −6,710 | $29.26 | $196K | 11,293 |
| 2026-03-30 | Dandekar Atul CSBO | Sale 10b5-1 | −790 | $30.02 | $24K | 10,503 |
| 2026-03-30 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 51,643 |
Page 6 of 14 · 267 trades